PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

PacBio designs, manufactures, and sells genomic sequencing systems, microchips, and reagents built on its proprietary Single-Molecule Real-Time sequencing technology. Its products, which include Revio, Vega, and Sequel instruments alongside SMRT Cells and specialized assay kits, enable high-accuracy long-read sequencing of DNA and RNA. Researchers deploy these tools across rare disease research, human germline analysis, oncology, infectious disease surveillance, and plant and animal biology. The company supplies academic and governmental institutions, commercial laboratories, clinical research facilities, hospitals, agricultural enterprises, and biopharmaceutical organizations.

The company operates a primary manufacturing and service facility in Menlo Park, California, supported by domestic and international contract manufacturers. It markets and distributes its sequencing platforms worldwide through a direct sales organization alongside distribution partners across Europe, Australia, parts of Asia, the Middle East, Africa, Central America, and South America.

Summary of the business section of Pacific Biosciences Of California's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 485 full-time employees.”